Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

N. Hortobágyi, Gabriel; M. Stemmer, Salomon; A. Burris, Howard; Sim Yap, Yoon; S. Sonke, Gabe; Paluch–Shimon, Shani; Campone, Mario; Blackwell, Kimberly; André, Fabrice; P. Winer, Eric; Janni, Wolfgang; Verma, Sunil; Conte, PierFranco; L. Arteaga, Carlos; Cameron, David; Petráková, Katarína; L. Hart, Lowell; Villanueva, Cristian; Chan, Arlene; Jakobsen, Erik; Nusch, Arnd; Burdaeva, Olga; Grischke, Eva‐Maria; Alba, Emilio; Wist, Erik; Marschner, Norbert; Favret, Anne; A. Yardley, Denise; Bachelot, Thomas; Tseng, Ling-Ming; Blau, Sibel; Xuan, Fengjuan; Souami, Farida; C. Miller, Michelle; Germa, Caroline; Hirawat, Samit; O’Shaughnessy, Joyce

doi:10.1056/nejmoa1609709

Public

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Published in New England Journal of Medicine • Oct 8, 2016

Authors:

Gabriel N. Hortobágyi

Salomon M. Stemmer

Howard A. Burris

Abstract

BACKGROUND: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). METHODS: . RESULTS: for s...

Subject

Medicine

Hazard ratio

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!